Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TEDA Unveils Plan For Biopharmaceutical Industry

This article was originally published in PharmAsia News

Executive Summary

The Tianjin Economic-Technological Development Area recently unveiled its plans for the biopharmaceutical industry. By 2015, it aims to establish a biopharmaceutical industry worth RMB 50 billion, attracting more than 40 large manufacturing enterprises and targeting export rates of 30 percent. TEDA seeks to be an important Asia-Pacific pharmaceutical R&D and manufacturing hub with links to international contract research and manufacturing organizations. A biopharmaceutical industry cluster will be set up to integrate pharmaceutical MNCs, local leading companies and small- and medium-sized innovative enterprises. TEDA aims to develop its own unique characteristics in the CRO, CMO and medical device domains, nurture a core batch of leading pioneers for Tianjin's biopharmaceutical industry and make breakthroughs in new drug creation. (Click here for more - Chinese Language)

You may also be interested in...

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts